Mark Middleton
Consultant Medical Oncologist and Professor of Experimental Cancer Medicine · University of Oxford, UK · Churchil Hospital, Oxford, UK
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark Middleton as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05315258 · Tebentafusp in Molecular Relapsed Disease (MRD) MelanomaUniversity of Oxford · active not recruiting · Melanoma (Skin), Melanoma, Uveal · principal investigator
- Ph1NCT04852367 · PanDox: Targeted Doxorubicin in Pancreatic TumoursUniversity of Oxford · withdrawn · Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV, Pancreatic Cancer Non-resectable · principal investigator
- Ph1/Ph2NCT02735239 · Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerLudwig Institute for Cancer Research · completed · Esophageal Cancer · study chair
- Ph2NCT00936221 · Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma PatientsAstraZeneca · completed · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:13 UTC. The ranking covers the 200 most relevant of 138 PubMed records, and a shared surname and initials can bring in a namesake. All 138 on PubMed
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.J Clin Oncol · 20152,144 citationsRCR 63.6
- Improved survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med · 20122,097 citationsRCR 54.1
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.N Engl J Med · 20171,847 citationsRCR 59.7
- Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.J Clin Oncol · 2000978 citationsRCR 20.3
- 505 citationsRCR 15.0
- Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.Hepatology · 2013463 citationsRCR 15.7
- 450 citationsRCR 18.5
- The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population.Br J Cancer · 2005402 citationsRCR 12.7
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.J Immunother Cancer · 2019381 citationsRCR 13.4
- Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.J Clin Oncol · 2018370 citationsRCR 11.7